Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $28.88

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been given a consensus recommendation of “Hold” by the five brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.50.

A number of analysts have commented on the stock. Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 5th. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Finally, Guggenheim started coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 target price on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its holdings in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares in the last quarter. Indivisible Partners bought a new position in X4 Pharmaceuticals in the 4th quarter worth approximately $40,000. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals during the 4th quarter valued at approximately $50,000. Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals during the 3rd quarter valued at approximately $47,000. Finally, Palumbo Wealth Management LLC raised its position in shares of X4 Pharmaceuticals by 18.9% during the fourth quarter. Palumbo Wealth Management LLC now owns 113,357 shares of the company’s stock valued at $453,000 after buying an additional 18,030 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR opened at $4.04 on Friday. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $8.40. The firm has a market capitalization of $367.32 million, a P/E ratio of -0.93 and a beta of 0.43. The company has a quick ratio of 9.98, a current ratio of 10.16 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $3.70 and a 200-day moving average price of $3.65.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.14. The firm had revenue of $2.57 million for the quarter, compared to analysts’ expectations of $1.68 million. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. Equities research analysts anticipate that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.